Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Karabajakian, A."'
Autor:
Le Meitour, Yannick, Foy, Jean-Philippe, Guinand, Mathilde, Michon, Lucas, Karabajakian, Andy, Fayette, Jérôme, Saintigny, Pierre, Mahtouk, Karène
Publikováno v:
In Oral Oncology February 2024 149
Autor:
Karabajakian, Andy, Genestie, Catherine, Meeus, Pierre, Guyon, Frédéric, Llacer Moscardo, Carmen, Croce, Sabrina, Taieb, Sophie, Duffaud, Florence, Pautier, Patricia, Ray-Coquard, Isabelle, Blay, Jean-Yves
Publikováno v:
In Bulletin du Cancer July-August 2023 110(7-8):836-843
Autor:
Jean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, Maxime Boussageon, Lucas Michon, Jebrane Bouaoud, Dorssafe Fekiri, Marie Robert, Kim-Arthur Baffert, Geneviève Hervé, Pauline Quilhot, Valéry Attignon, Angélique Girod, André Chaine, Mourad Benassarou, Philippe Zrounba, Christophe Caux, François Ghiringhelli, Sylvie Lantuejoul, Carole Crozes, Isabelle Brochériou, Maurice Pérol, Jérôme Fayette, Chloé Bertolus, Pierre Saintigny
Publikováno v:
Data in Brief, Vol 44, Iss , Pp 108556- (2022)
Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. In this co
Externí odkaz:
https://doaj.org/article/dc4e546ef4f94d60bcf8550d81ded5eb
Autor:
Karabajakian, Andy, Bouaoud, Jebrane, Michon, Lucas, Kamal, Maud, Crozes, Carole, Zrounba, Philippe, Auclair-Perossier, Jessie, Gadot, Nicolas, Attignon, Valéry, Le Tourneau, Christophe, Benzerdjeb, Nazim, Fayette, Jérôme, Saintigny, Pierre
Publikováno v:
In Oral Oncology August 2021 119
Autor:
Barak Rotblat, Andreas Mock, Jerome Fayette, Limor Cohen, Idan Cohen, Elena Voronov, Jebrane Bouaoud, Lucas Michon, Pierre Saintigny, Luc G T Morris, Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B Shnerb, Sooraj Mathukkada, Ofra Novoplansky, Mai Badarni, Ksenia M Yegodayev, Sapir Tzadok, Libor Brezina, Andy Karabajakian, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Moshe Elkabets
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown clinically meaningful activity. Therefore, we aimed to characterize the effect o
Externí odkaz:
https://doaj.org/article/e52b0f83da384bc987314eeb1cc6f2e4
Publikováno v:
In Oral Oncology August 2019 95:164-169
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer worldwide. More than half of HNSCC patients experience locoregional or distant relapse to treatment despite aggressive multimodal therapeutic approaches that include surg
Externí odkaz:
https://doaj.org/article/208f4db2033f46b8a7232cb7ebb375ce
Autor:
Karabajakian, Andy1,2,3 (AUTHOR) andy.karabajakian@lyon.unicancer.fr, Ray-Coquard, Isabelle1,2,3 (AUTHOR) isabelle.ray-coquard@lyon.unicancer.fr, Blay, Jean-Yves1,2,3 (AUTHOR) jean-yves.blay@lyon.unicancer.fr
Publikováno v:
Cancers. Apr2022, Vol. 14 Issue 8, p1869. 12p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jean-Philippe Foy, Andy Karabajakian, Sandra Ortiz-Cuaran, Maxime Boussageon, Lucas Michon, Jebrane Bouaoud, Dorssafe Fekiri, Marie Robert, Kim-Arthur Baffert, Geneviève Hervé, Pauline Quilhot, Valéry Attignon, Angélique Girod, André Chaine, Mourad Benassarou, Philippe Zrounba, Christophe Caux, François Ghiringhelli, Sylvie Lantuejoul, Carole Crozes, Isabelle Brochériou, Maurice Pérol, Jérôme Fayette, Chloé Bertolus, Pierre Saintigny
Publikováno v:
European Journal of Cancer. 174:287-298
Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd48498ad82f20b2b7800fef1c60d54
https://doi.org/10.1016/j.ejca.2022.06.034
https://doi.org/10.1016/j.ejca.2022.06.034